Histopathological growth patterns as a candidate biomarker for immunomodulatory therapy. (October 2018)

• Record Type: Journal Article
• Authors: van Dam, Pieter-Jan; Daelemans, Sofie; Ross, Elizabeth; Waumans, Yannick; Van Laere, Steven; Latacz, Emily; Van Steen, Roanne; De Pooter, Christel; Kockx, Mark; Dirix, Luc; Vermeulen, Peter B.
• Is Part Of: Seminars in cancer biology. Volume 52(2018)Part 2
• Page Start: 86
• Page End: 93
• Publication Date: 2018-10
• Subjects: CAF cancer-associated fibroblast -- CRC colorectal cancer -- FAP fibroblast activation protein -- H&E hematoxylin-and-eosin -- HGP histopathological growth pattern -- LSEC liver sinusoidal endothelial cells -- OS overall survival -- VEGF vascular endothelial growth factor -- VHL von Hippel-Lindau; Histopathological growth patterns -- Vessel co-option -- Angiogenesis -- Immune-evasive mechanisms -- Immunotherapy; Cancer -- Periodicals; Neoplasms -- Periodicals; Review Literature; Cancer -- Périodiques; Electronic journals; 616.994
• DOI: 10.1016/j.semcancer.2018.01.009
• Languages: English
• ISSNs: 1044-579X

Abstract

Abstract: The encroachment of a growing tumor upon the cells and structures of surrounding normal tissue results in a series of histopathological growth patterns (HGPs). These morphological changes can be assessed in hematoxylin-and-eosin (H&E) stained tissue sections from primary and metastatic tumors and have been characterized in a range of tissue types including liver, lung, lymph node and skin. HGPs in different tissues share certain general characteristics like the extent of angiogenesis, but also appropriate tissue-specific mechanisms which ultimately determine differences in the biology of HGP subtypes. For instance, in the well-characterized HGPs of liver metastases, the two main subtypes, replacement and desmoplastic, recapitulate two responses of the normal liver to injury: regeneration and fibrosis. HGP subtypes have distinct cytokine profiles and differing levels of lymphocytic infiltration which suggests that they are indicative of immune status in the tumor microenvironment. HGPs predict response to bevacizumab and are associated with overall survival (OS) after surgery for liver metastases in colorectal cancer (CRC). In addition, HGPs can change over time in response to therapy. With standard scoring methods being developed, HGPs represent an easily accessible, dynamic biomarker to consider when determining strategies for treatment using anti-VEGF and immunomodulatory drugs.